IL37 and neoplasm: It inhibits DCs function in inflammatory settings (6), while enhances DCs function in tumor models, for example, hepatocellular carcinoma (HCC) cells that overexpressing IL-37 could secrete more specific chemokines (such as CCL3 and CCL20) to increase the infiltration density of DCs in tumor sites; in addition, IL-37 could stimulate DCs to produce higher levels of cytokines such as IFN-γ, thereby indirectly strengthen the anti-tumor activity of T lymphocytes (86).